SCHEMBL19472154

SCHEMBL19472154

O=c1oc2ccc(-n3c4ccccc4c4cc5c6ccccc6n(-c6ccccc6)c5cc43)cc2c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.47
MAPK1 P28482 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ATM Q13315 1/20 0.46
ALDH2 P05091 1/20 0.41
CA9 Q16790 5/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
BRCA1 P38398 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
RXFP1 Q9HBX9 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16925932 0.92 KDM4E (0.46) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL19472153 0.91 L3MBTL1 (0.45) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL19472152 0.90 NPSR1 (0.47) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL16925681 0.90 KDM4E (0.46) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL16925779 0.89 KDM4E (0.51) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL16925928 0.89 SMN1; SMN2 (0.46) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL16925924 0.88 ALDH2 (0.49) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL16925684 0.87 KDM4E (0.46) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL19472214 0.87 L3MBTL1 (0.46) KMT2AMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL16925864 0.87 ALDH2 (0.46) KMT2AMAPK1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3197887-B1 HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2020-09-23 EP disclosed
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures MERCK PATENT GMBH (DE) 2019-08-13 US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 US disclosed
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES MERCK PATENT GMBH (DE) 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298077-A1 HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES NISCH, SIRT3, NQO1 KMT2A 3494/4885MAPK1 2068/4885NPC1 1598/4885
US-10377766-B2 Heterocyclic compounds with benzo(c)coumarin-structures NISCH, SIRT3, NQO1 KMT2A 3494/4885MAPK1 2068/4885NPC1 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.